Use of 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Rare Head and Neck Cancers
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives. The clinical utility of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has been demonstrated in major head and neck cancers (HNCs) but is unclear in rare HNCs. We therefore evaluated FDG PET in the management of patients with rare HNCs. Methods. FDG PET and CT/MRI scanning were performed at the initial staging and/or the follow-up in 24 patients with rare HNCs, 10 with melanoma, 9 with sarcoma, 3 with olfactory neuroblastomas, and 2 with basal cell carcinoma. The diagnostic accuracy of CT and FDG PET for detecting primary tumors and metastases were compared with a histopathologic reference. The association between the PET results and the clinicopathologic parameters predicting tumor invasion, histologic grade and disease-free survival (DFS), was assessed. Results. The overall accuracies of FDG PET and CT/MRI were 92% and 79%, respectively, for detecting primary tumors and 91% and 74%, respectively, for nodal metastases, but the differences were not significant due to the small number of patients. The sensitivity and specificity of FDG PET for detecting distant metastases and second primary tumors were 100% and 87%, respectively. Follow-up FDG PET correctly diagnosed locoregional recurrence in all 12 patients, as shown by biopsy, and distant metastases in 6 patients. However, thickness of melanoma, histologic grade of sarcoma, and DFS were not associated with tumor FDG uptake. Conclusion. FDG PET may be useful for staging, posttreatment monitoring, and detection of distant metastases and second primary tumors in patients with rare HNCs.
Abstract
Objectives. The clinical utility of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has been demonstrated in major head and neck cancers (HNCs) but is unclear in rare HNCs. We therefore evaluated FDG PET in the management of patients with rare HNCs. Methods. FDG PET and CT/MRI scanning were performed at the initial staging and/or the follow-up in 24 patients with rare HNCs, 10 with melanoma, 9 with sarcoma, 3 with olfactory neuroblastomas, and 2 with basal cell carcinoma. The diagnostic accuracy of CT and FDG PET for detecting primary tumors and metastases were compared with a histopathologic reference. The association between the PET results and the clinicopathologic parameters predicting tumor invasion, histologic grade and disease-free survival (DFS), was assessed. Results. The overall accuracies of FDG PET and CT/MRI were 92% and 79%, respectively, for detecting primary tumors and 91% and 74%, respectively, for nodal metastases, but the differences were not significant due to the small number of patients. The sensitivity and specificity of FDG PET for detecting distant metastases and second primary tumors were 100% and 87%, respectively. Follow-up FDG PET correctly diagnosed locoregional recurrence in all 12 patients, as shown by biopsy, and distant metastases in 6 patients. However, thickness of melanoma, histologic grade of sarcoma, and DFS were not associated with tumor FDG uptake. Conclusion. FDG PET may be useful for staging, posttreatment monitoring, and detection of distant metastases and second primary tumors in patients with rare HNCs.
참고문헌 (29)
- Jemal A, "Cancer statistics", CA Cancer J Clin, 57(1), pp.43~66 (2007)
- Zimmer LA, "Current use of 18F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck", Laryngoscope, 115(11), pp.2029~2034 (2005)
- Menda Y, "Update on 18F-fluorodeoxyglucose", positron emission tomography and positron emission tomography, Semin Nucl Med, pp.2005, 35(4)[DOI]
- Kostakoglu L, "Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma", Cancer, 94(4), pp.879~888 (2002)
- Schoder H, "Positron emission imaging of head and neck cancer, including thyroid carcinoma", Semin Nucl Med, 34(3), pp.180~197 (2004)
- Rohren EM, "Clinical applications of PET in oncology", Radiology, 231(2), pp.305~332 (2004)
- Adams S, "Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer", Eur J Nucl Med, 25(9), pp.1255~1260 (1998)
- Stokkel MP, "Preoperative evaluation of patients with primary head and neck cancer using dual-head 18fluorodeoxyglucose positron emission tomography", Ann Surg, 231(2), pp.229~234 (2000)
- Kresnik E, "Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods", Eur J Nucl Med, 28(7), pp.816~821 (2001)
- Roh JL, "Clinical utility of 18F-FDG PET for patients with salivary gland malignancies", J Nucl Med, 48(2), pp.240~246 (2007)
- fluro-2-deoxy-D-glucose positron emission tomography imaging in nonsquamous tumors of the head and neck, "Invest Radiol", 2003, 593~601
- Goerres GW, "FDG PET for mucosal malignant melanoma of the head and neck", Laryngoscope, 112(2), pp.381~385 (2002)
- Fosko SW, "Positron emission tomography for basal cell carcinoma of the head and neck", Arch Dermatol, 139(9), pp.1141~1146 (2003)
- Kadish S, "Olfactory neuroblastoma. A clinical analysis of 17 cases", Cancer, 37(3), pp.1571~1576 (1976)
- American Joint Committee on Cancer, "AJCC Cancer Staging Manual", pp.187~220 (2002), Springer-Verlag
- Som PM, "Imaging-based nodal classification for evaluation of neck metastatic adenopathy", AJR Am J Roentgenol, 174(3), pp.837~844 (2000)
- Kienstra MA, "Head and neck melanoma", Cancer Control, 12(4), pp.242~247 (2005)
- Kumar R, "Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma", Curr Opin Oncol, 17(2), pp.154~159 (2005)
- Mijnhout GS, "Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients", Cancer, 91(8), pp.1530~1542 (2001)
- Clark PB, "Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma", Arch Surg, 141(3), pp.284~288 (2006)
- Wagner JD, "Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma", Cancer, 104(3), pp.570~579 (2005)
- Mendenhall WM, "Adult head and neck soft tissue sarcomas", Head Neck, 27(10), pp.916~922 (2005)
- fluorodeoxyglucose positron emission tomography, "Eur J Nucl Med Mol Imaging", 2006, 683~691
- Schuetze SM, "Utility of positron emission tomography in sarcomas", Curr Opin Oncol, 18(4), pp.369~373 (2006)
- fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas, "Ann Surg", 2005, 286~294
- Lund VJ, "Olfactory neuroblastoma: past, present, and future?", Laryngoscope, 113(3), pp.502~507 (2003)
- Rinaldo A, "Esthesioneuroblastoma and cervical lymph node metastases: clinical and therapeutic implications", Acta Otolaryngol, 122(2), pp.215~221 (2002)
- Brouwer J, "Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET?", Oral Oncol, 42(3), pp.275~280 (2006)
- fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging, "J Clin Oncol", 2005, 7654~7659